PMV Pharma Q3 net loss widens to $21.1 mln

Pmv Pharmaceuticals

12/11/2025 13:09

Overview

PMV Pharmaceuticals reports Q3 net loss of $21.1 mln, driven by increased R&D costs

Company ends Q3 with $129.3 mln in cash, runway until Q1 2027

Clinical study shows 34% ORR across cohorts, 46% in ovarian cancer

Outlook

PMV Pharma plans NDA submission for rezatapopt in Q1 2027

Company expects cash runway to end of Q1 2027

Result Drivers

R&D EXPENSES - Increased R&D costs due to advancement of rezatapopt program

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.40
Q3 Net Income
-$21.06 mln
Q3 Operating Expenses
$22.52 mln
Q3 Operating Income
-$22.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.50, about 79.5% above its November 11 closing price of $1.33

Press Release: ID:nGNX8X65kX

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)